EP. 1: OneOncology’s Duncan Allen, MHA, Discusses Bringing CAR T-cell Therapy to the Community Setting
The vice president for Clinical Services at OneOncology describes challenges and opportunities for chimeric antigen receptor (CAR) T-cell therapy in the community practice setting.
EP. 2: Gaining Knowledge of CAR T-Cell Therapy, and CRS, Over Time
EP. 3: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel
City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.
EP. 4: Real-World Data Offer Good News for CAR T-Cell Therapy
Karl Kilgore, PhD, a senior research scientist at Avalere Health, discusses Medicare data that offer insights on the overall costs of CAR T-cell therapy relative to transplants.
EP. 5: Deepu Madduri, MD, Discusses CARTITUDE-1 Data for Multiple Myeloma—and Clinical Trials During COVID-19
At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.
EP. 6: Moving a Step Closer to Using CAR T-Cell Therapy in Solid Tumors
A recent paper in Nature Cancer outlines a novel strategy for overcoming barriers to CAR T-cell therapy in glioblastoma by pretreating the vascular microenvironment.
EP. 7: Delays Mean Some Miss Window for CAR T-Cell Therapy, Cardinal Health Data Show
Data gathered by Cardinal Health Specialty Solutions revealed roadblocks community oncology practices encounter when trying to navigate payer approvals for CAR T-cell therapy.
2 Clarke Drive Cranbury, NJ 08512